

68mm

145mm

Liveaf رولاف ۲۵، ۵۰، ۱۰۰ ملی گرام گولیاں

[Levosulpiride]
25mg, 50mg & 100mg Tablets

DESCRIPTION:

LIVLAF (Levosulpiride) is a substituted benzamide derivative and a selective dopamine D2 antagonist. It has been used therapeutically as an antidepressant, antipsychotic, and as a digestive aid.

QUALITATIVE AND QUANTITATIVE COMPOSITION:

LIVLAF (Levosulpiride) is available for oral administration as:

1. LIVLAF Tablets 25mg

Each tablet contains:

Levosulpiride.....25mg

(Product Specs.: Sigma)

2. LIVLAF Tablets 50mg

Each tablet contains:

Levosulpiride.....50mg

(Product Specs.: Sigma)

3. LIVLAF Tablets 100mg

Each tablet contains:

Levosulpiride.....100mg

(Product Specs.: Sigma)

CLINICAL PHARMACOLOGY:

Mechanism of Action:

Levosulpiride is a selective antagonist at dopamine (D2) receptors with antipsychotic and antidepressant activity. Levosulpiride exerts a regulation action both on the central and peripheral nervous circuits controlling the dynamics of digestive system. Levosulpiride appears to lack effects on norepinephrine, acetylcholine, serotonin, histamine, or gamma-aminobutyric acid (GABA) receptors.

Pharmacokinetics:

Levosulpiride is slowly absorbed from the gastrointestinal tract, bioavailability is about 30%. Levosulpiride is less than 40% bound to plasma proteins. Peak plasma concentration occurs after 3 hours and it has plasma half life of about 9.7 hours. It is mostly eliminated by the kidneys in the urine, chiefly as unchanged drug.

THERAPEUTIC INDICATIONS:

LIVLAF tablets are indicated for oral administration:

LIVLAF 25mg tablets are indicated for treatment of the following:

– Gastroesophageal reflux disease.

– Irritable bowel syndrome.

– Dyspeptic syndrome due to delayed gastric emptying linked to organic factor (diabetic gastroparesis, neoplasias, etc.) and/or to functional disorder.

– Essential Cephalalgia.

– Vertigo of a central and/or peripheral origin.

LIVLAF 50mg tablets are indicated for treatment of the following:

– Endogenous and reactive depressive states.

– Somatic disorder.

LIVLAF 100mg tablets are indicated for treatment of the following:

– Acute and chronic schizophrenia especially recommended for negative symptoms (after disorder).

DOSAGE AND ADMINISTRATION:

The usual adult oral dose of LIVLAF is given before meals as mentioned in the following table:

Indications	Dosage	Maintenance Therapy
-Gastroesophageal Reflux Disease (GERD) -Irritable Bowel Syndrome (IBS) -Dyspeptic syndrome -Essential cephalalgia -Vertigo of a central and/or Peripheral origin.	1 tablet of 25mg 3 times a day	
-Endogenous reactive depressive states -Somatic disorder	2-3 tablets 50mg a day	Unless otherwise prescribed, 3 tablets of 50mg per day This dose can be reduced gradually
- Acute and chronic Schizophrenia	2-3 tablets 100mg a day	

Special Population:

Geriatric Use:

The dosage may be progressively lowered. In treating aged patients the dosage must be carefully established by the physician who must consider a possible reduction in the dosage mentioned above.

CONTRAINDICATIONS:

LIVLAF is contraindicated in following conditions:

– Patients with known hypersensitivity to levosulpiride or any component of this product

– In epilepsy, in manic conditions and in the manic stages of manic depressive psychoses.

– Patients with hyperprolactinemic tendency, mammary dysplasia malignant mastopathy.

– Patients affected by pheochromocytoma as it may cause a hypertensive crisis, probably due to release of catecholamine from the tumor.

– In the presence of gastrointestinal bleeding, mechanical obstruction or perforations.

– Pediatric population.

PRECAUTIONS:

LIVLAF should be used with care in the following conditions:

– Patients receiving levosulpiride should be warned that at higher doses somnolence, numbness and dyskinesia might occur, therefore patients should avoid driving vehicles or operate machineries.

– If held to be essential for re-treatment with antipsychotics, the patient should be carefully monitored.

– Use with caution in patients with cardiovascular disease or with a family history of QT prolongation.

– Avoid the simultaneous consumption of alcohol.

Pregnancy and Lactation:

LIVLAF is contraindicated in pregnancy and lactation.

DRUG INTERACTIONS:

General:

– Avoid concomitant therapy with other drugs that prolong the QT, risk of cardiac arrhythmias increase.

– Not to be administered concomitantly with the drugs that cause electrolyte disturbance.

Antacids:

The concomitant use of levosulpiride with therapeutic doses of sucralfate or an antacid containing aluminium and magnesium hydroxide may reduce mean oral bioavailability of levosulpiride.

Anticholinergics, narcotics or analgesics agents:

The effect of levosulpiride on the gastrointestinal motility may be opposed by anticholinergics, narcotics or analgesic agents.

Psychopharmacological agents:

Concomitant use with other psychopharmacologic agents requires particular care and vigilance by the physician, in order to avoid any unexpected side effect or drug –drug interaction.

ADVERSE EFFECTS:

Following adverse effects of levosulpiride have been reported.

Very common: sedation and hypotension.

Common: Dizziness and vertigo.

Rare: QT prolongation, ventricular arrhythmias, ventricular tachycardia, ventricular fibrillation, cardiac arrest.

Very rare: Weight gain, tremor, rigidity, postural instability, involuntary muscle movements, dystonia, psychomotor agitation (unintentional and purposeless motions and restlessness), disorders of the autonomic nervous system.

Not known: Neuroleptic Malignant Syndrome (life-threatening reaction, symptoms include hyperpyrexia, muscle rigidity, difficulty in movement, irregular pulse or blood pressure, sweating, tachycardia, arrhythmias, amenorrhea, gynaecomastia, galactorrhea, changes in libido, extrapyramidal symptoms (drug-induced movement disorders) and hyperlactaemia.

OVERDOSAGE:

Tremors, difficulty and slowness in movement (extrapyramidal disorders) or sleep disorders may occur with the highest doses. Interrupting the therapy or reducing the doses depending should be considered.

INSTRUCTIONS:

– Store below 30°C.

– Protect from light & moisture.

– Keep out of reach of children.

To be sold on prescription of a registered medical practitioner.

PRESENTATION

LIVLAF (Levosulpiride) tablets 25mg are available in pack of 10's.

LIVLAF (Levosulpiride) tablets 50mg are available in pack of 20's.

LIVLAF (Levosulpiride) tablets 100mg are available in pack of 20's.

توراک: ذاکو کی ہاریت کے مطابق استعمال کریں۔

ہاریت: دوا کو ۳۰ ڈگری سینٹی گریڈ سے کم درجہ حرارت پر رکھیں۔

دستی کوئی سے چاہیں۔ بچوں کی نگاہ سے دور رکھیں۔

صرف دہرہ ڈاکٹر کے نسخے کے مطابق فروخت کریں۔

Manufactured by:
SIGMA PHARMA International (Pvt.) Ltd,
E-50 North Western Industrial Zone,
Port Qasim Authority, Karachi-Pakistan,
www.sigmapharma.com.pk